Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company based in Brookhaven, Town of, NY. They are at the forefront of developing a new class of oncology treatments and cancer therapies known as PP2A inhibitors. Their lead molecule, LB-100, has shown remarkable synergy with chemotherapy and immunotherapy in pre-clinical models, offering potential enhancements to both treatment modalities.
With a focus on increasing the efficacy of existing cancer treatments, Lixte Biotechnology Holdings aims to provide better outcomes for a wide range of patients. Their proprietary compound, LB-100, acts as an inhibitor of the PP2A phosphatase, a critical enzyme involved in multiple cellular functions. Through their innovative approach, Lixte Biotechnology Holdings is dedicated to transforming cancer treatment and revolutionizing the landscape of cancer care.
Generated from the website
Also at this address
You might also like
Partial Data by Foursquare.

